Antihyperglycemic therapies and cardiovascular outcomes in patients with type 2 diabetes mellitus: State of the art and future directions

Eri Toda Kato; Sandeep R. Das; Darren K. McGuire

doi:10.1016/j.tcm.2019.12.010

Antihyperglycemic therapies and cardiovascular outcomes in patients with type 2 diabetes mellitus: State of the art and future directions

Eri Toda Kato, Sandeep R. Das, Darren K. McGuire

Research output: Contribution to journal › Review article › peer-review

5 Scopus citations

Abstract

Type 2 diabetes mellitus is a progressive chronic disease and is an established risk factor for cardiovascular disease. Until recently, the cardiovascular safety and efficacy of antihyperglycemic drugs remained uncertain. However, after the changes in regulatory guidance in 2008, a wealth of data has been generated, expanding the focus of the treatment of diabetes from blood glucose control to the prevention of macro-and microvascular complications and improvement in mortality. This article will review cardiovascular outcome trials of antihyperglycemic agents and provide overview of ongoing trials.

Original language	English (US)
Pages (from-to)	101-108
Number of pages	8
Journal	Trends in Cardiovascular Medicine
Volume	31
Issue number	2
DOIs	https://doi.org/10.1016/j.tcm.2019.12.010
State	Published - Feb 2021

Keywords

Antihyperglycemic
Cardiovascular outcome trials
Type 2 diabetes mellitus

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

Access to Document

10.1016/j.tcm.2019.12.010

Cite this

@article{a3dc6a76c6d149f3b3cb745ecb2f7358,

title = "Antihyperglycemic therapies and cardiovascular outcomes in patients with type 2 diabetes mellitus: State of the art and future directions",

abstract = "Type 2 diabetes mellitus is a progressive chronic disease and is an established risk factor for cardiovascular disease. Until recently, the cardiovascular safety and efficacy of antihyperglycemic drugs remained uncertain. However, after the changes in regulatory guidance in 2008, a wealth of data has been generated, expanding the focus of the treatment of diabetes from blood glucose control to the prevention of macro-and microvascular complications and improvement in mortality. This article will review cardiovascular outcome trials of antihyperglycemic agents and provide overview of ongoing trials.",

keywords = "Antihyperglycemic, Cardiovascular outcome trials, Type 2 diabetes mellitus",

author = "Kato, {Eri Toda} and Das, {Sandeep R.} and McGuire, {Darren K.}",

note = "Publisher Copyright: {\textcopyright} 2020",

year = "2021",

month = feb,

doi = "10.1016/j.tcm.2019.12.010",

language = "English (US)",

volume = "31",

pages = "101--108",

journal = "Trends in Cardiovascular Medicine",

issn = "1050-1738",

publisher = "Elsevier Inc.",

number = "2",

}

TY - JOUR

T1 - Antihyperglycemic therapies and cardiovascular outcomes in patients with type 2 diabetes mellitus

T2 - State of the art and future directions

AU - Kato, Eri Toda

AU - Das, Sandeep R.

AU - McGuire, Darren K.

PY - 2021/2

Y1 - 2021/2

N2 - Type 2 diabetes mellitus is a progressive chronic disease and is an established risk factor for cardiovascular disease. Until recently, the cardiovascular safety and efficacy of antihyperglycemic drugs remained uncertain. However, after the changes in regulatory guidance in 2008, a wealth of data has been generated, expanding the focus of the treatment of diabetes from blood glucose control to the prevention of macro-and microvascular complications and improvement in mortality. This article will review cardiovascular outcome trials of antihyperglycemic agents and provide overview of ongoing trials.

AB - Type 2 diabetes mellitus is a progressive chronic disease and is an established risk factor for cardiovascular disease. Until recently, the cardiovascular safety and efficacy of antihyperglycemic drugs remained uncertain. However, after the changes in regulatory guidance in 2008, a wealth of data has been generated, expanding the focus of the treatment of diabetes from blood glucose control to the prevention of macro-and microvascular complications and improvement in mortality. This article will review cardiovascular outcome trials of antihyperglycemic agents and provide overview of ongoing trials.

KW - Antihyperglycemic

KW - Cardiovascular outcome trials

KW - Type 2 diabetes mellitus

UR - http://www.scopus.com/inward/record.url?scp=85078160319&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85078160319&partnerID=8YFLogxK

U2 - 10.1016/j.tcm.2019.12.010

DO - 10.1016/j.tcm.2019.12.010

M3 - Review article

C2 - 31982285

AN - SCOPUS:85078160319

SN - 1050-1738

VL - 31

SP - 101

EP - 108

JO - Trends in Cardiovascular Medicine

JF - Trends in Cardiovascular Medicine

IS - 2

ER -

Antihyperglycemic therapies and cardiovascular outcomes in patients with type 2 diabetes mellitus: State of the art and future directions

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this